LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Aktien・Design Therapeutics Inc

Design Therapeutics Inc

Geschlossen

7.35 3.96

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.29

Max

7.49

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.1M -17M
Gewinnspanne	-2,321.599
Angestellte	55
EBITDA	2.4M -19M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-18.59% downside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	50M 423M
Vorheriger Eröffnungskurs	3.39
Vorheriger Schlusskurs	7.35

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

3.26 / 3.63 Unterstützung & Widerstand

Design Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Nov. 2025, 17:45 UTC

Ergebnisse

Wichtige Markttreiber

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. Nov. 2025, 17:31 UTC

Ergebnisse

Wichtige Markttreiber

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

16. Nov. 2025, 23:40 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

16. Nov. 2025, 23:36 UTC

Market Talk

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

16. Nov. 2025, 23:26 UTC

Market Talk

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

16. Nov. 2025, 16:20 UTC

Ergebnisse

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

15. Nov. 2025, 09:20 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

15. Nov. 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15. Nov. 2025, 00:08 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14. Nov. 2025, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. Nov. 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. Nov. 2025, 22:35 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. Nov. 2025, 22:32 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. Nov. 2025, 22:29 UTC

Ergebnisse

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. Nov. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. Nov. 2025, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

14. Nov. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. Nov. 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. Nov. 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. Nov. 2025, 20:17 UTC

Akquisitionen, Fusionen, Übernahmen

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. Nov. 2025, 19:29 UTC

Market Talk

Ergebnisse

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. Nov. 2025, 18:44 UTC

Market Talk

Ergebnisse

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. Nov. 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

14. Nov. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. Nov. 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. Nov. 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Peer-Vergleich

Kursveränderung

Design Therapeutics Inc Prognose

Kursziel

By TipRanks

-18.59% Nachteil

12-Monats-Prognose

Durchschnitt 6 USD -18.59%

Hoch 6 USD

Tief 6 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Design Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Design Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

3.26 / 3.63Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.